Anti-inflammatory and antioxidant effects of a hypoglycemic fructan fraction from Psacalium peltatum (H.B.K.) Cass. in streptozotocin-induced diabetes mice

Journal of Ethnopharmacology

Volumn 132, Issue 2, 2010, Pages 400-407

  Alarcon Aguilar, F J ^a   Fortis Barrera, A ^a   Angeles Mejia, S ^a   Banderas Dorantes, T R ^a   Jasso Villagomez, E I ^a   Almanza Perez, J C ^a   Blancas Flores, G ^a   Zamilpa, A ^b   Diaz Flores, M ^c   Roman Ramos, R ^a  

^a UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UIM Bioquímica CMN Siglo XXI Social Security Mexican Institute   (Mexico)

Author keywords

Antioxidant activity; Asteraceae; Cytokines; Diabetes mellitus; Fructans; Hypoglycemic plants; Psacalium peltatum

Indexed keywords

ANTIDIABETIC AGENT; FRUCTAN; GAMMA INTERFERON; GLUCOSE; GLUTATHIONE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 6; MALONALDEHYDE; PIOGLITAZONE; PLANT EXTRACT; PSACALIUM PELTATUM EXTRACT; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLANT ROOT; PSACALIUM PELTATUM; STREPTOZOCIN DIABETES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ASTERACEAE; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FRUCTANS; HYPOGLYCEMIC AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-6; MICE; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; ASTERACEAE; MUS; PSACALIUM PELTATUM;

EID: 78049365061     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.08.003     Document Type: Article

References (48)

1. Alarcon-Aguilar F.J., Roman-Ramos R. Investigation of anti-diabetic plants in Mexico. Trends and Advances in Medicinal Plants 2008 2008, 36-49. Research Signpost, Trivandrum, Kerala, India. Maria Salud Perez Gutierrez (Ed.).
2. Alarcon-Aguilar F.J., Roman-Ramos R., Jimenez-Estrada M., Reyes-Chilpa R., Gonzalez-Paredes B., Flores-Saenz J.L. Effects of three Mexican medicinal plants (Asteraceae) on blood glucose levels in healthy mice and rabbits. Journal of Ethnopharmacology 1997, 55:171-177.
3. Bailey C.J. Treating insulin resistance: future prospects. Diabetes and Vascular Disease Research 2007, 4:20-31.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
5. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., Franklin R.A., McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17:590-603.
6. Chaudhry J., Ghosh N.N., Roy K., Chandra R. Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life Sciences 2007, 80:1135-1142.
7. Chavez E., Henry R.R. Type 2 diabetes: insulin resistance, beta cell dysfunction, and other metabolic and hormonal abnormalities. Clinical Diabetes: Translating Research into Practice 2005, 21-35. WB Saunders Co., USA. V.A. Fonseca (Ed.).
8. Contreras-Weber C.C., Perez-Gutiérrez S., Alarcon-Aguilar F.J., Roman-Ramos R. Antihyperglycemic effect of Psacalium peltatum extracts. Proceedings of the Western Pharmacology Society 2002, 45:128-130.
9. Contreras-Weber C.C., Roman-Ramos R., Perez C., Alarcon-Aguilar F.J., Zavala M.A., Perez-Gutierrez S. Hypoglycemic activity of a new carbohydrate isolated from the roots of Psacalium peltatum. Chemical and Pharmaceutical Bulletin 2005, 53:1408-1410.
10. Cruz M., Maldonado-Bernal C., Mondragon-Gonzalez R., Sanchez-Barrera R., Wacher N.H., Carvajal-Sandoval G., Kumate J. Journal of Endocrinology Investigation 2008, 31:694-699.
11. Diaz F.M., Baiza G.L., Ibañez H.L., Pascoe L.D., Guzman G.A., Kumate R.J. Aspectos moleculares del daño tisular inducido por la hiperglucemia crónica. Gaceta Medica de Mexico 2004, 140:437-446.
12. Dillard C.J., Bruce G.J. Phytochemical: nutraceuticals and human health. Journal of the Science of Food and Agriculture 2000, 80:1756-1774.
13. Dominiczak M.H. Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. Clinical Chemistry of Laboratory Medicine 2003, 41:1266-1278.
14. Draper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods in Enzymology 1990, 186:421-423.
15. Emanuelli B., Peraldi P., Filloux C., Sawka-Verhelle D., Hilton D., Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. Journal of Biological Chemistry 2000, 275:15985-15991.
16. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., Quagliaro L., Ceriello A., Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106:2067-2072.
17. Evans L.J. Antioxidants: do they have a role in the treatment of insulin resistance?. Indian Journal of Medical Research 2007, 125:355-372.
18. Fang Y.Z., Yang S., Wu G. Free radicals, antioxidants and nutrition. Nutrition 2002, 18:872-879.
19. Fernandez P., Kaski J.C. Interleucina-10 y enfermedad coronaria. Revista Española de Cardiologia 2002, 55:738-750.
20. Foss-Freitas M.C., Foss N.T., Donadi E.A., Foss M.C. Effect of metabolic control on interferon-gamma and interleukin-10 production by peripheral blood mononuclear cells from type 1 and type 2 diabetic patients. Brazilian Journal of Medicine and Biology Research 2007, 40:671-677.
21. Fujisawa K., Nishikawa T., Kukidome D., Imoto K., Yamashiro T., Motoshima H., Matsumura T., Araki E. TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochemical and Biophysical Research Communications 2009, 379:43-48.
22. Ganster R.W., Guo Z., Shao L., Geller D.A. Differential effects of TNF-alpha and IFN-gamma on gene transcription mediated by NF-kappaB-Stat1 interactions. Journal of Interferon Cytokine Research 2005, 25:707-719.
23. Girndt M., Kohler H. Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrology Dialysis Transplantation 2003, 18:1976-1979.
24. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes and Metabolism 2004, 30:13-19.
25. Hernandez C., Gonzalez V., Fuentes A., Cesar R., Gonzalez B., Garcia E. Citocinas proinflamatorias en la infeccion de tejidos blandos de pacientes diabeticos. Revista Medica del IMSS 2004, 42:227-233.
26. Johansen J.S., Harris A.K., Rychly D.J., Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovascular Diabetology 2005, 4:5.
27. Karin M. The beginning of the end: IκB kinase (IKK) and NF-κB activation. Journal of Biological Chemistry 1999, 274:27339-27342.
28. Linares E., Bye R.A. A study of four medicinal plant complexes of Mexico and adjacent United States. Journal of Ethnopharmcaology 1987, 19:153-183.
29. Marchesi Ch., Schiffrin L.E. Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects. Journal of the American Society of Hypertension 2008, 2:227-238.
30. Meister A., Anderson M.E. Glutathione. Annual Review of Biochemistry 1983, 52:711-760.
31. Mendivil, C.O., Sierra, I.D., 2005. Acción insulinica y resistencia a la insulina: aspectos moleculares. Revista de la Facultad de Medicina de la Universidad Nacional de Colombia 53, 235-243.
32. Moller D.E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends in Endocrinology and Metabolism 2000, 11:212-217.
33. Niehoff A.G., van Haeften T.W., Onland-Moret N.Ch., Elbers C.C., Wijmenga C., van der Schouw Y.T. C-reactive protein is independently associated with glucose but not with insulin resistance in healthy men. Diabetes Care 2007, 30:1627-1629.
34. Pastore A., Fedirici G., Bertini E., Piemonte F. Analysis of glutathione: implications in redox and detoxification. Clinical Chemistry Acta 2003, 333:19-39.
35. Ranjbaran H., Sokol S.I., Gallo A., Eid R.E., Iakimov A.O., D'Alessio A., Kapoor J.R., Akhtar S., Howes C.J., Aslan M., Pfau S., Pober J.S., Tellides G. An inflammatory pathway of IFN-γ production in coronary atherosclerosis. Journal of Immunology 2007, 178:592-604.
36. Rivera, N.M.E., Almanza, P.J.C., Perez, A.C., Ruiz, A.C., Vega, A.E., Alarcon, A.F.J., 2004. Estudio fitoquimico preliminar de extractos y fracciones de origen vegetal con actividad hipoglucemiante. IX Simposio del Departamento de Ciencias de la Salud Universidad Autonoma Metropolitana-Iztapalapa, September 22, 2004, p. 74 (Abstract).
37. Roman-Ramos R., Lara L.A., Alarcon-Aguilar F.J., Flores S.J.L. Hypoglycemic activity of some antidiabetic plants. Archives of Medical Research 1992, 23:105-109.
38. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and non-protein sulphydril groups in tissue with Ellman's reagent. Analytical Biochemistry 1968, 25:192-205.
39. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., Mooney R.A. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6 dependent insulin resistance in hepatocytes. Journal of Biological Chemistry 2003, 278:13740-13746.
40. Shain E, Güsmüslü S. Immobilization stress in rat tissues: alterations in protein oxidation, lipid peroxidation and antioxidant defense system. Comparative Biochemistry and Physiology C 2007, 144:342-347.
41. Sjöholm D., Nyström T. Endothelial inflammation in insulin resistance. The Lancet 2005, 365:610-612.
42. Steinberg G.R. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 2007, 6:888-894.
43. Tataranni P.A., Ortega E. Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?. Diabetes 2005, 54:917-927.
44. Toba H., Miki S., Shimizu T., Yoshimura A., Inoue R., Hawai N., Tsukamoto R., Murakami M., Morita Y., Nakayama Y., Kobara M., Nakata T. The direct antioxidative and anti-inflammatory effects of peroxisome proliferators-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta. European Journal of Pharmacology 2006, 549:124-132.
45. Unger J. Reducing oxidative stress in patient with type 2 diabetes mellitus: a primary care call to action. Insulin 2008, 3:176-184.
46. Waite K.J., Floyd Z.E., Arbour-Reily P., Stephens J.M. Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. Journal of Biological Chemistry 2001, 276:7062-7068.
47. Wright J.R., Scism J.L., Glass L.C. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. International Journal of Clinical Practice 2006, 60:308-314.
48. Zozulinska D., Wierusz-Wysocka Type 2 diabetes mellitus as inflammatory disease. Diabetes Research and Clinical Practice 2006, 74:S12-S16.